Alnylam Shares Rise After Strong 2Q, FDA Fast Track Designation

Dow Jones

Aug 01, 2025

By Josh Beckerman

Shares of Alnylam Pharmaceuticals hit a 52-week high after it posted a strong quarter and said a heart-disease treatment received Food and Drug Administration Fast Track Designation.

The stock was up 16%, to $394.20, midday Thursday, with an intraday high of $402.43. Shares are up about 68% this year.

The Cambridge, Mass., company said the FDA awarded Fast Track Designation to nucresiran, a treatment for cardiomyopathy of wild-type or hereditary transthyretin mediated amyloidosis.

Alnylam reported that second-quarter net product revenue rose 64%, to $672 million, with total revenue up 17%, to $773.7 million. The company increased its full-year net product revenue guidance range to $2.65 billion to $2.8 billion from $2.05 billion to $2.25 billion.

Adjusted earnings per share declined to 32 cents from 56 cents, but were above the average estimate of 2 cents from analysts polled by FactSet. The company posted higher expenses for sales, general and administrative costs as well as research and development.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

July 31, 2025 14:10 ET (18:10 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2556830753"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556830753\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556830753?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-01 02:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556830753","market":"sh","top_or_hot":-1,"title":"Alnylam Shares Rise After Strong 2Q, FDA Fast Track Designation","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ALNY\">Alnylam Pharmaceuticals</a> hit a 52-week high after it posted a strong quarter and said a heart-disease treatment received Food and Drug Administration <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation. \n</p>\n<p>\n  The stock was up 16%, to $394.20, midday Thursday, with an intraday high of $402.43. Shares are up about 68% this year. \n</p>\n<p>\n  The Cambridge, Mass., company said the FDA awarded Fast Track Designation to nucresiran, a treatment for cardiomyopathy of wild-type or hereditary transthyretin mediated amyloidosis. \n</p>\n<p>\n  Alnylam reported that second-quarter net product revenue rose 64%, to $672 million, with total revenue up 17%, to $773.7 million. The company increased its full-year net product revenue guidance range to $2.65 billion to $2.8 billion from $2.05 billion to $2.25 billion. \n</p>\n<p>\n  Adjusted earnings per share declined to 32 cents from 56 cents, but were above the average estimate of 2 cents from analysts polled by FactSet. The company posted higher expenses for sales, general and administrative costs as well as research and development. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 31, 2025 14:10 ET (18:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam Shares Rise After Strong 2Q, FDA Fast Track Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam Shares Rise After Strong 2Q, FDA Fast Track Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-01 02:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ALNY\">Alnylam Pharmaceuticals</a> hit a 52-week high after it posted a strong quarter and said a heart-disease treatment received Food and Drug Administration <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation. \n</p>\n<p>\n  The stock was up 16%, to $394.20, midday Thursday, with an intraday high of $402.43. Shares are up about 68% this year. \n</p>\n<p>\n  The Cambridge, Mass., company said the FDA awarded Fast Track Designation to nucresiran, a treatment for cardiomyopathy of wild-type or hereditary transthyretin mediated amyloidosis. \n</p>\n<p>\n  Alnylam reported that second-quarter net product revenue rose 64%, to $672 million, with total revenue up 17%, to $773.7 million. The company increased its full-year net product revenue guidance range to $2.65 billion to $2.8 billion from $2.05 billion to $2.25 billion. \n</p>\n<p>\n  Adjusted earnings per share declined to 32 cents from 56 cents, but were above the average estimate of 2 cents from analysts polled by FactSet. The company posted higher expenses for sales, general and administrative costs as well as research and development. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 31, 2025 14:10 ET (18:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2556830753","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556830753","pubTimestamp":1753985400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Alnylam Pharmaceuticals hit a 52-week high after it posted a strong quarter and said a heart-disease treatment received Food and Drug Administration Fast Track Designation.The stock was up 16%, to $394.20, midday Thursday, with an intraday high of $402.43. Shares are up about 68% this year.The Cambridge, Mass., company said the FDA awarded Fast Track Designation to nucresiran, a treatment for cardiomyopathy of wild-type or hereditary transthyretin mediated amyloidosis.Alnylam reported that second-quarter net product revenue rose 64%, to $672 million, with total revenue up 17%, to $773.7 million. The company increased its full-year net product revenue guidance range to $2.65 billion to $2.8 billion from $2.05 billion to $2.25 billion.Adjusted earnings per share declined to 32 cents from 56 cents, but were above the average estimate of 2 cents from analysts polled by FactSet. The company posted higher expenses for sales, general and administrative costs as well as research and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4104":"贸易公司与经销商","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","ALNY":"阿尔尼拉姆制药公司","BK4567":"ESG概念","FAST":"快扣","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓"},"translate_title":"Alnylam股价在第二季度强劲并获得FDA快速通道指定后上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":0.9,"FAST":1},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Shares of Alnylam Pharmaceuticals hit a 52-week high after it posted a strong quarter and said a heart-disease treatment received Food and Drug Administration Fast Track Designation. \n\n\n  The stock was up 16%, to $394.20, midday Thursday, with an intraday high of $402.43. Shares are up about 68% this year. \n\n\n  The Cambridge, Mass., company said the FDA awarded Fast Track Designation to nucresiran, a treatment for cardiomyopathy of wild-type or hereditary transthyretin mediated amyloidosis. \n\n\n  Alnylam reported that second-quarter net product revenue rose 64%, to $672 million, with total revenue up 17%, to $773.7 million. The company increased its full-year net product revenue guidance range to $2.65 billion to $2.8 billion from $2.05 billion to $2.25 billion. \n\n\n  Adjusted earnings per share declined to 32 cents from 56 cents, but were above the average estimate of 2 cents from analysts polled by FactSet. The company posted higher expenses for sales, general and administrative costs as well as research and development. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 31, 2025 14:10 ET (18:10 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}